.pf{position:relative;background-color:#fff;overflow:hidden;margin:0;border:0}.pc{position:absolute;border:0;padding:0;margin:0;top:0;left:0;width:100%;height:100%;overflow:hidden;display:block;transform-origin:0 0;-ms-transform-origin:0 0;-webkit-transform-origin:0 0}.bi{position:absolute;border:0;margin:0}.t{position:absolute;white-space:pre;font-size:1px;transform-origin:0 100%;-ms-transform-origin:0 100%;-webkit-transform-origin:0 100%;unicode-bidi:bidi-override;-moz-font-feature-settings:"liga" 0}.t:after{content:''}.t:before{content:'';display:inline-block}.t span{position:relative;unicode-bidi:bidi-override}._{display:inline-block;color:transparent;z-index:-1}.pi{display:none}@media screen{.pf{margin:13px auto;box-shadow:1px 1px 3px 1px #333;border-collapse:separate}}.ff1{font-family:ff1;line-height:1.205000;font-style:normal;font-weight:400;visibility:visible}@font-face{font-family:ff2;src:url(data:application/font-woff;base64,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) format("woff")}.ff2{font-family:ff2;line-height:.722656;font-style:normal;font-weight:400;visibility:visible}.m0{transform:matrix(.320260,0,0,.320260,0,0);-ms-transform:matrix(.320260,0,0,.320260,0,0);-webkit-transform:matrix(.320260,0,0,.320260,0,0)}.ls2{letter-spacing:0}.ls1{letter-spacing:24px}.ls0{letter-spacing:33.888px}.sc0{text-shadow:-.015em 0 transparent,0 .015em transparent,.015em 0 transparent,0 -.015em transparent}@media screen and (-webkit-min-device-pixel-ratio:0){.sc0{-webkit-text-stroke:.015em transparent;text-shadow:none}}.ws0{word-spacing:-12px}.ws1{word-spacing:0}._2{margin-left:-3.84px}._0{margin-left:-1.824px}._1{width:1.056000px}.fc1{color:#000}.fc0{color:red}.fs0{font-size:48px}.y27{bottom:125.029657px}.y26{bottom:143.732864px}.y25{bottom:161.79555px}.y24{bottom:179.473923px}.y23{bottom:198.17713px}.y22{bottom:216.239816px}.y21{bottom:234.943023px}.y20{bottom:254.030542px}.y1f{bottom:272.093228px}.y1e{bottom:289.771602px}.y1d{bottom:307.449976px}.y1c{bottom:326.153183px}.y1b{bottom:345.240702px}.y1a{bottom:363.303388px}.y0{bottom:378.547783px}.y19{bottom:380.981761px}.y18{bottom:416.338509px}.y17{bottom:434.016882px}.y16{bottom:454.129235px}.y15{bottom:472.191921px}.y14{bottom:491.407544px}.y13{bottom:509.085918px}.y12{bottom:529.198271px}.y11{bottom:547.260957px}.y10{bottom:566.47658px}.yf{bottom:601.833327px}.ye{bottom:620.536534px}.yd{bottom:639.624054px}.yc{bottom:658.711573px}.yb{bottom:677.799092px}.ya{bottom:695.861778px}.y9{bottom:713.540152px}.y8{bottom:731.218525px}.y7{bottom:766.575273px}.y6{bottom:801.932020px}.y5{bottom:819.610393px}.y4{bottom:837.288767px}.y3{bottom:872.645514px}.y2{bottom:890.323888px}.y1{bottom:908.002261px}.h3{height:34.6875px}.h2{height:44.352px}.h1{height:222.260712px}.h0{height:1014.58492px}.w1{width:93.516034px}.w0{width:783.997438px}.x0{left:115.293741px}.x2{left:138.480593px}.x4{left:151.803425px}.x3{left:161.539341px}.x5{left:174.862174px}.x1{left:184.598090px}

PHAR 100 Study Guide - Midterm Guide: Agonist, Helminths

Canada

Introductory Pharmacology

Pharmacology and Toxicology

Prof.

Queen's University

Introductory Biology of Cells

Introductory Biology of Organisms

General Chemistry

PHAR 100 Study Guide - Midterm Guide: Muscle Relaxant, Nicotinic Acetylcholine Receptor, Sympathetic Nervous System

PHAR 100 Lecture Notes - Clinical Trial, Asthma, Osteoporosis

PHAR 100 Lecture Notes - Lecture 2: Postmarketing Surveillance, Clinical Trial, Biological Target

PHAR 100 Study Guide - Midterm Guide: Agonist, Helminths

Get access

Related Documents

PHAR 100 Study Guide - Midterm Guide: Muscle Relaxant, Nicotinic Acetylcholine Receptor, Sympathetic Nervous System

PHAR 100 Lecture Notes - Clinical Trial, Asthma, Osteoporosis

PHAR 100 Lecture Notes - Lecture 2: Postmarketing Surveillance, Clinical Trial, Biological Target